NDAINJECTIONINJECTABLE
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
ETOPOPHOS PRESERVATIVE FREE (etoposide phosphate) by Bristol Myers Squibb is 12. Approved for germ cell tumor. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETOPOPHOS PRESERVATIVE FREE is an intravenous injection of etoposide phosphate, a prodrug that converts to etoposide in plasma. It is a topoisomerase II inhibitor indicated for germ cell tumors that works by inducing DNA strand breaks and arresting cells at the G2 phase. The preservative-free formulation reduces excipient burden in vulnerable patient populations.
LOE Approaching
Product is in late-stage lifecycle with no current linked job openings; team is likely in maintenance/transition mode rather than growth.
Mechanism of Action
12.1 Mechanism of Action Etoposide phosphate is a prodrug that is converted to its active moiety, etoposide, by dephosphorylation. Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest,…
Worked on ETOPOPHOS PRESERVATIVE FREE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.